TABLE 6.
Pertactin type comparison within periods between isolates from vaccinated and unvaccinated individuals during trial I, as well as for the surveillance years (1997-2000)
| Pertactin type | Trial I (1992-1995)a
|
Surveillance (1997-2000)b
|
||
|---|---|---|---|---|
| Vaccinated | Placebo | Vaccinated | Unvaccinated | |
| 1/7 | 8 (19%) | 8 (7%) | 15 (5%) | 20 (4%) |
| 2 | 31 (74%) | 93 (85%) | 218 (78%) | 406 (83%) |
| 3 | 3 (7%) | 6 (5%) | 46 (16%) | 61 (13%) |
| Other prn types | 3 (3%) | 1 (0%) | ||
| Total | 42 (100%) | 110 (100%) | 279 (100%) | 488 (100%) |
a
P = 0.08 within period.
b
P = 0.15 within period.